SI9725: MLN2238

LifeSensors SI9725 (MLN2238) is a selective, reversible proteasome inhibitor targeting the chymotrypsin-like β5 site, used in cancer research and drug discovery.

$310.00

SKU SI-9725-0005 Categories Proteasome Inhibitors, Small Molecule Modulators and PROTACs

In stock

Product Advantages

Applications

Inhibition of chymotrypsin-like proteasome catalytic activity.
Cellular studies of proteasome inhibition.

MLN2238 is a proteasome inhibitor. Much like Bortezomib, MLN2238 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treatment for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.

Info

Purity	>99% (HPLC), NMR (conforms)
Quantity	5 mg
Molecular Weight	361.03 Da
Physical State	Lyophilized powder
Solubility	DMSO (72 mg/mL); ethanol (9 mg/mL)
CAS No.	1072833-77-2
Storage	4°C, (-20°C Long term). The product can be shipped at room temperature.